UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Hepatology (Baltimore, Md.), 2018-10, Vol.68 (4), p.1298-1307

2018

Volltextzugriff (PDF)

Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

The AAPS journal, 2008-12, Vol.10 (4), p.537-551

2008

Volltextzugriff (PDF)

Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens

PloS one, 2018-05, Vol.13 (5), p.e0198296

2018

Volltextzugriff (PDF)

Dynamic changes in innate immune responses during direct‐acting antiviral therapy for HCV infection

Journal of viral hepatitis, 2019-03, Vol.26 (3), p.362-372

2019

Volltextzugriff (PDF)

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

Clinical pharmacokinetics, 2016-08, Vol.55 (8), p.1003-1014

2016

Volltextzugriff (PDF)

Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A

Journal of medicinal chemistry, 2014-03, Vol.57 (5), p.2047-2057

2014

Volltextzugriff (PDF)

Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

The AAPS journal, 2008-12, Vol.10 (4), Article 537

2008

Volltextzugriff (PDF)

Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy

The International journal of drug policy, 2019-04, Vol.66, p.73-79

2019

Volltextzugriff (PDF)

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

The lancet. Gastroenterology & hepatology, 2017-07, Vol.2 (7), p.494-500

2017

Volltextzugriff (PDF)

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage

The Journal of infectious diseases, 2018-01, Vol.217 (3), p.474-482

2018

Volltextzugriff (PDF)

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability

Journal of medicinal chemistry, 2018-02, Vol.61 (3), p.1153-1163

2018

Volltextzugriff (PDF)

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1002-S-1002

2015

Volltextzugriff (PDF)

Tu1024 Plasma Interferon-γ-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1087-S-1088

2015

Volltextzugriff (PDF)

Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics

Journal of clinical pharmacology, 2024-08, Vol.64 (8), p.975-983

2024

Volltextzugriff (PDF)

A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers

Clinical pharmacology in drug development, 2014-07, Vol.3 (4), p.314-320

2014

Volltextzugriff (PDF)

Premenstrual dysphoric disorder and sexual function: a narrative review

Sexual medicine reviews, 2023-06, Vol.11 (3), p.202-211

2023

Volltextzugriff (PDF)

GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection: 888

The American journal of gastroenterology, 2016-10, Vol.111, p.S388

2016

Volltextzugriff (PDF)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study

Nephrology, dialysis, transplantation, 2012-05, Vol.27 (5), p.1942-1949

2012

Volltextzugriff (PDF)

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials

Open forum infectious diseases, 2018-11, Vol.5 (11), p.ofy248-ofy248

2018

Volltextzugriff (PDF)

141 Baseline Characteristics of Subjects in Impact-Shpt: A Study to Evaluate the Efficacy and Safety of Paricalcitol and Cinacalcet in Hemodialysis Patients With Secondary Hyperparathyroidism

American journal of kidney diseases, 2011, Vol.57 (4), p.B52-B52

2011

Volltextzugriff (PDF)

Autism spectrum disorder

Nature reviews. Disease primers, 2020-01, Vol.6 (1), p.5-5, Article 5

2020

Volltextzugriff (PDF)

Children's active outdoor play: ‘good’ mothering and the organisation of children's free time

Sociology of health & illness, 2020-07, Vol.42 (6), p.1229-1242

2020

Volltextzugriff (PDF)

TAF-ID: An international thermodynamic database for nuclear fuels applications

Calphad, 2021-03, Vol.72, p.102212, Article 102212

2021

Volltextzugriff (PDF)

Extending poly-victimization theory: Differential effects of adolescents’ experiences of victimization on substance use disorder diagnoses upon treatment entry

Child abuse & neglect, 2019-03, Vol.89, p.165-177

2019

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection

Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens

Dynamic changes in innate immune responses during direct‐acting antiviral therapy for HCV infection

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A

Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective

Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy

Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques

1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials

Tu1024 Plasma Interferon-γ-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis

Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics

A food effect study and dose proportionality study to assess the pharmacokinetics and safety of bardoxolone methyl in healthy volunteers

Premenstrual dysphoric disorder and sexual function: a narrative review

GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection: 888

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials

141 Baseline Characteristics of Subjects in Impact-Shpt: A Study to Evaluate the Efficacy and Safety of Paricalcitol and Cinacalcet in Hemodialysis Patients With Secondary Hyperparathyroidism

Autism spectrum disorder

Children's active outdoor play: ‘good’ mothering and the organisation of children's free time

TAF-ID: An international thermodynamic database for nuclear fuels applications

Extending poly-victimization theory: Differential effects of adolescents’ experiences of victimization on substance use disorder diagnoses upon treatment entry

Suchergebnisse filtern